Talk:Fosbretabulin

Pharmacology Low‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Low	This article has been rated as Low-importance on the project's importance scale.

Chemicals Low‑importance

	This article is within the scope of WikiProject Chemicals, a daughter project of WikiProject Chemistry, which aims to improve Wikipedia's coverage of chemicals. To participate, help improve this article or visit the project page for details on the project.ChemicalsWikipedia:WikiProject ChemicalsTemplate:WikiProject Chemicalschemicals articles
Low	This article has been rated as Low-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Fosbretabulin.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Link added

I've added a link back to the main Combretastatin page, as there's much more info about it on there. I wonder if this stub is actually needed, or could be merged back into the main combretastatin page? KatArney (talk) 12:27, 4 May 2011 (UTC)[reply]

Better IMO to keep this separate. Combretastatin is about a whole family of natural molecules. This CA4P is about one specific experimental drug which has undergone numerous clinical trials; which should be summarised (here). - Rod57 (talk) 15:13, 16 February 2017 (UTC)[reply]

List of references

The following list of references was added to the article, but apparently are not used to support specific content in the article. I'm moving them here in case anyone would like to use them to expand this article. -- Ed (Edgar181) 19:19, 16 August 2011 (UTC)[reply]

Beauregard, D; Hill, S; Chaplin, D; Brindle, K. The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlated with vascular permeability Cancer Research, 2001, 61, 6811-6815.
Salmon, B. “Characterizing the Tumor Response to Treatment with Combretastatin A-4 Phosphate” Int. J. Radiation Oncology Biol. Phys, 2007, 68, 1, 211-217

Two isomers ?

Combretastatin A-4 says it comes in two isomers - only cis being active. Does this apply to CA4P too ? - Rod57 (talk) 11:20, 17 February 2017 (UTC)[reply]